HCPCS J8502 is officially defined as "Injection, aprepitant (aponvie), 1 mg." HCPCS J8502 is referenced in 12 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, BCBS Michigan, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J8502 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of Rhode Island updated HCPCS Level II code coverage and payment rules effective April 1, 2026. Multiple codes have new coverage designations including newly covered codes, non-covered codes, medical review requirements, and pharmacy benefit changes.
Blue Cross Blue Shield of Michigan has implemented its Q1 2026 HCPCS code updates, adding 56 new codes and deleting 6 codes effective April 1, 2026. Most new skin substitute codes (A2040-A2045, Q4418-Q4440) are not covered, while new drug/injection codes (J-codes) and COVID-19 related codes are generally covered.
Arkansas Medicaid is implementing new HCPCS and CPT procedure codes effective April 1, 2026, while simultaneously terminating four codes (C9145, C9307, C9308, L6000, L6010, L6020). Billing teams must update systems to recognize new payable codes by provider type, implement new prior authorization requirements for specific codes, and process mass adjustments to recoup any claims paid with terminated codes after March 31, 2026.
Texas Medicaid is implementing first quarter 2026 HCPCS updates effective April 1, 2026, adding new covered and non-covered procedure codes with specific age limitations and prior authorization requirements. Several existing codes are being discontinued with direct replacements required.
Texas Medicaid CSHCN Services Program is implementing Q1 2026 HCPCS updates effective April 1, 2026. Multiple codes are being added as benefits (pending rate hearings), added as non-covered, or discontinued entirely. Several new codes require prior authorization and have age restrictions.
Texas Medicaid (TMHP) has updated reimbursement rates for HCPCS code J8502 effective April 1, 2026. The new rates apply to the Children with Special Health Care Needs (CSHCN) Services Program. TMHP will automatically identify and reprocess affected claims, with adjustments appearing on future Remittance and Status Reports.
Kansas Medicaid (KMAP) is adding 13 new HCPCS codes for coverage and discontinuing 6 existing codes effective April 1, 2026. Billing teams must update their systems to use the new codes and stop billing the discontinued ones.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes added in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. Codes marked noncovered are not covered for any IHCP program. Pricing for the new codes depends on CMS fee schedules that were still awaiting final posting, and claims submitted before pricing is entered into the claim-processing system may initially be denied.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. This bulletin replaces the originally published update in IHCP Bulletin BT202649, and it sets prior authorization criteria for J3404, J9183, and the Q5161 and Q5162 biosimilars. Codes discontinued effective March 31, 2026 have no alternative codes identified by the IHCP, and codes marked allowed for podiatrists (provider specialty 140) are limited to that provider specialty.
CMS established new HCPCS codes for 8 specialty medical drugs effective April 1, 2026, replacing temporary codes. The billing team must update their systems to use the new permanent codes for all services performed on or after April 1, 2026, while continuing to use old codes for services through March 31, 2026.
Michigan Medicaid has updated CPT and HCPCS codes effective April 1, 2026, adding new covered codes for various provider types and discontinuing several existing codes. The policy also includes retroactive coverage for some codes back to January 1, 2026.
Aetna Clinical Policy Bulletin 0724, Antiemetic Therapy, was reviewed 2026-07-17. It lists the antiemetic uses Aetna considers medically necessary and the uses it considers experimental, investigational or unproven. The source text does not state an effective date or describe what changed.
Watch J8502
Get one email when a payer policy names J8502, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J8502
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J8502 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.